XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) | 6 Months Ended
--- | ---
Sep. 27, 2025
Segment Reporting [Abstract] |
Selected Information by Business Segment | Selected information by reportable segment is presented below:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
Net revenues: |  |  |  |  |  |  |
Plasma | $ | 125,364 |  |  | $ | 138,561 |  |  | $ | 255,261 |  |  | $ | 274,471 |
Blood Center | 56,454 |  |  | 68,528 |  |  | 108,293 |  |  | 134,773 |
Hospital | 145,497 |  |  | 138,422 |  |  | 285,155 |  |  | 272,439 |
Total net revenues | $ | 327,315 |  |  | $ | 345,511 |  |  | $ | 648,709 |  |  | $ | 681,683 |
Significant segment expenses and operating performance: |  |  |  |  |  |  |
Plasma |  |  |  |  |  |  |
Cost of goods sold | $ | 53,019 |  |  | $ | 65,726 |  |  | $ | 102,936 |  |  | $ | 131,064 |
Selling, general and administrative | 24,761 |  |  | 25,262 |  |  | 50,959 |  |  | 50,392 |
Research and development | 4,993 |  |  | 3,147 |  |  | 10,490 |  |  | 6,866 |
Plasma operating income | $ | 42,591 |  |  | $ | 44,426 |  |  | $ | 90,876 |  |  | $ | 86,149 |
Blood Center |  |  |  |  |  |  |
Cost of goods sold | $ | 26,948 |  |  | $ | 36,311 |  |  | $ | 52,896 |  |  | $ | 72,491 |
Selling, general and administrative | 13,504 |  |  | 15,202 |  |  | 27,186 |  |  | 30,804 |
Research and development | 1,177 |  |  | 1,213 |  |  | 2,496 |  |  | 2,897 |
Blood Center operating income | $ | 14,825 |  |  | $ | 15,802 |  |  | $ | 25,715 |  |  | $ | 28,581 |
Hospital |  |  |  |  |  |  |
Cost of goods sold | $ | 49,318 |  |  | $ | 47,706 |  |  | $ | 99,534 |  |  | $ | 96,391 |
Selling, general and administrative | 57,966 |  |  | 58,806 |  |  | 120,289 |  |  | 119,996 |
Research and development | 8,352 |  |  | 8,633 |  |  | 17,094 |  |  | 16,256 |
Hospital operating income | $ | 29,861 |  |  | $ | 23,277 |  |  | $ | 48,238 |  |  | $ | 39,796 |
Corporate and unallocated expenses |  |  |  |  |  |  |
Amortization of acquired intangible assets | $ | (13,237) |  |  | $ | (16,003) |  |  | $ | (27,065) |  |  | $ | (33,713) |
Acquisition, integration and divestiture related costs | (1,520) |  |  | (882) |  |  | (4,202) |  |  | (13,205) |
Restructuring and restructuring related costs | (258) |  |  | (6,363) |  |  | (1,582) |  |  | (13,503) |
Digital transformation costs | (5,054) |  |  | (4,858) |  |  | (10,409) |  |  | (11,203) |
Other(1) | (8,717) |  |  | (3,702) |  |  | (9,208) |  |  | 8,551 |
Operating income | 58,491 |  |  | 51,697 |  |  | 112,363 |  |  | 91,453 |
Interest and other expense, net | (7,206) |  |  | (6,993) |  |  | (15,909) |  |  | (36) |
Income before provision for income taxes | $ | 51,285 |  |  | $ | 44,704 |  |  | $ | 96,454 |  |  | $ | 91,417 |
Schedule of Revenues by Business Unit and Geographic Regions | Net revenues by business unit are as follows:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
Plasma |  |  |  |  |  |  |
Plasma net revenues | $ | 125,364 |  |  | $ | 138,561 |  |  | $ | 255,261 |  |  | $ | 274,471 |
Blood Center |  |  |  |  |  |  |
Apheresis | 56,065 |  |  | 54,332 |  |  | 107,887 |  |  | 103,426 |
Whole Blood | 389 |  |  | 14,196 |  |  | 406 |  |  | 31,347 |
Blood Center net revenues | 56,454 |  |  | 68,528 |  |  | 108,293 |  |  | 134,773 |
Hospital |  |  |  |  |  |  |
Interventional Technologies | 59,073 |  |  | 61,923 |  |  | 117,556 |  |  | 124,967 |
Blood Management Technologies | 86,424 |  |  | 76,499 |  |  | 167,599 |  |  | 147,472 |
Hospital net revenues | 145,497 |  |  | 138,422 |  |  | 285,155 |  |  | 272,439 |
Total net revenues | $ | 327,315 |  |  | $ | 345,511 |  |  | $ | 648,709 |  |  | $ | 681,683 |
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
Plasma | $ | 12,033 |  |  | $ | 12,032 |  |  | $ | 24,186 |  |  | $ | 23,948 |
Blood Center | 1,849 |  |  | 2,737 |  |  | 3,608 |  |  | 6,190 |
Hospital | 14,373 |  |  | 14,448 |  |  | 29,219 |  |  | 28,215 |
Total depreciation and amortization (excluding impairment charges) | $ | 28,255 |  |  | $ | 29,217 |  |  | $ | 57,013 |  |  | $ | 58,353 |
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
| September 27, 2025 |  | March 29, 2025
| (Dollars in Thousands)
Plasma | $ | 204,258 |  |  | $ | 189,833 |
Blood Center | 39,455 |  |  | 40,337 |
Hospital | 55,304 |  |  | 53,882 |
Total long-lived assets | $ | 299,017 |  |  | $ | 284,052 |
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
| September 27, 2025 |  | March 29, 2025
| (Dollars in Thousands)
United States | $ | 223,664 |  |  | $ | 217,212 |
Japan | 1,195 |  |  | 1,250 |
Europe | 25,292 |  |  | 20,024 |
Rest of Asia | 30,940 |  |  | 28,705 |
Other | 17,926 |  |  | 16,861 |
Total long-lived assets | $ | 299,017 |  |  | $ | 284,052 |
Net revenues by operating regions are as follows:
| Three Months Ended |  | Six Months Ended
| September 27, 2025 |  | September 28, 2024 |  | September 27, 2025 |  | September 28, 2024
| (Dollars in Thousands)
United States | $ | 240,089 |  |  | $ | 256,061 |  |  | $ | 482,493 |  |  | $ | 504,963 |
Japan | 18,011 |  |  | 16,424 |  |  | 31,659 |  |  | 30,129 |
Europe | 42,965 |  |  | 41,991 |  |  | 83,847 |  |  | 89,216 |
Rest of Asia | 22,567 |  |  | 25,768 |  |  | 44,215 |  |  | 45,551 |
Other | 3,683 |  |  | 5,267 |  |  | 6,495 |  |  | 11,824 |
Total net revenues | $ | 327,315 |  |  | $ | 345,511 |  |  | $ | 648,709 |  |  | $ | 681,683 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration